ArticleAbdominal radiology (New York)2026
Deep learning for automatic detection of hepatocellular carcinoma in dynamic contrast-enhanced MRI.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveDevelop a deep learning model for automatic hepatocellular carcinoma (HCC) detection in T1 weighted imaging (WI) Dynamic Contrast-Enhanced (DCE) liver MRI using extracellular contrast agent, and to analyze its performance at both patient and lesion levels. MATERIALS AND
methodsThis retrospective study included two cohorts, the first included patients (N = 296) undergoing HCC surveillance with diagnosed HCC as well as negative cases. The 233 HCC negative patients and 12 HCC positive patients were used to create the HCC Surveillance test set, aiming to evaluate patient level performance on simulated screening conditions. The second included Pre-Ablation patients (N = 67), all positive for HCC, used as test set for lesion level evaluation and to measure generalization performance. The two largest public liver lesion datasets (CT, N = 1037 and MRI, N = 485) were used for pre-training the algorithms. An attention U-Net model was trained to segment and detect HCC and was compared to the state-of-art nnU-Netv2. Diagnostic accuracy was evaluated using sensitivity, specificity, mean false positives per patient, PPV and NPV, the Area Under the Curve (AUC) of the Free-Response Operating Characteristic (FROC) curves and the Receiver Operating Characteristic (ROC) curves.
resultsThe final population included 363 patients (58 ± 11 years; 284 men; 247 lesions): 51 HCC positive patients (113 lesions) used in training set, 245 patients (12 HCC positive with 21 lesions, 233 HCC negative) in the HCC Surveillance testing set, 67 HCC positive patients (113 lesions) in the HCC Pre-Ablation testing set. At patient level, 83% sensitivity and 72% specificity [AUC of 0.80 (95% CI: 0.66-0.91)] was measured on the HCC Surveillance test set. At lesion level, 80% of sensitivity for a mean false positive per patient of 1 was measured on the HCC Pre-Ablation test set with the pre-trained model with a FROC AUC of 0.82 (95% CI: 0.77-0.88), significantly outperforming the nnU-Netv2 at 0.61 (95% CI: 0.52-0.69, p < 0.01).
conclusionsBoth patient-level and lesion-level achieved 80% HCC detection sensitivity by using a deep learning segmentation neural network pre-trained from large open datasets. This performance highlights the translational potential of such tools in the clinical workup of patients at risk of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.